Kuros Biosciences Enters Agreement with Medtronic

Kuros Biosciences USA entered into a strategic five-year, exclusive sales agency agreement with Medtronic. The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market.

This agreement positions Kuros for new opportunities in the U.S. spine market and also paves the way for broader adoption of the MagnetOs family of products. This agreement transforms an initial trial agreement into a strategic alliance for a period of five years.

Chris Fair, Chief Executive Officer of Kuros Biosciences, commented: “What started as a trial agreement has now evolved into a strategic alliance with Medtronic reflecting an important milestone for Kuros. This agreement will also help us drive the scaling up process, further optimize our operating leverage, and continue our rapid revenue growth both with Medtronic and in our own direct channels.”

Source: Kuros Biosciences USA

Save Supplier